1065 Comparing the Adverse Effects of Ventral Pallidum and Anterior Thalamus Deep Brain Stimulation for Epilepsy in a Rodent Model
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: Epilepsy is the fourth most common neurological disease in the world, with a significant disease burden globally. Moreover, some individuals do not respond to antiepileptic drugs and are considered refractory, which can lead to higher mortality, and severe detriment to quality of life of physical and mental health. Deep brain stimulation shows great potential in delivering seizure relief in severe, refractory cases. However, current FDA-approved DBS targets such as anterior thalamus DBS continue to fall short in delivering adequate seizure freedom. This project advances the study of a novel DBS target, the ventral pallidum (VP), by first assessing whether neuromodulating this brain area elicits more or less adverse effects than the anterior thalamus. METHODS: Motor and cognitive behavioral testing was done on rats with or without receiving VP-DBS or ANT-DBS. Specifically, the limb use-asymmetry test (LAT) was used to assess acute motor deficit, whereas the novel object recognition test (NOR) assesses memory impairments. The fasted feeding behavior test (FFB) was used to reveal any changes in motivated appetitive behavior. For each test, a within-subject study design was employed with animals unstimulated the first week and then receiving DBS in the second week. All data were analyzed using GraphPad Prism using a one-way ANOVA, with a Kruskal-Wallis post hoc test. RESULTS: No significant differences in adverse effects were found across all assessed metrics between ANT-DBS (n = 8) and VP-DBS (n = 6). No difference in total limb touches, limb use asymmetry, or rearing behavior was observed (LAT). Similarly, there were no differences in familiar object recognition, and animals consumed similar amounts of food. CONCLUSIONS: VP-DBS did not elicit adverse effects with similar performance in forelimb function, cognition, and feeding behavior to those receiving ANT-DBS, the current FDA-approved standard of care for severe medically refractory epilepsy. Assessing whether VP-DBS is more efficacious than ANT-DBS remains to be investigated to underscore this as a promising DBS target for epilepsy.
Fields of Study & Subjects
Deep Brain Stimulation and Movement Disorders
Epilepsy research and treatment
Vagus Nerve Stimulation Research
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 194–194
- Publication date
- 26 March 2026
- Language
- EN